Abstract: Through analysis on an effective detection space of a gamma detector, a one-dimensional equivalent longitudinal contribution coefficient (varying with a distance between a formation and the detector) of a natural gamma-ray flux received by the gamma detector under the condition that the formation and a wellbore are orthogonal is obtained in the effective detection space, and then a corresponding function expression is given by fitting. An integral of a gamma-ray flux received by the detector under the condition of a deviated well is converted into a one-dimensional equivalent integral problem under the condition of a straight well, so as to achieve the fast forward of natural gamma-ray logging of the formation under the conditions of highly-deviated and horizontal wells. This simplified fast forward algorithm can replace a gamma forward method of spherical spatial-division integrals in parallel sedimentary formations, reduce a space-time complexity of algorithms, and improve a calculation efficiency.

Abstract: Through analysis on an effective detection space of a gamma detector, a one-dimensional equivalent longitudinal contribution coefficient (varying with a distance between a formation and the detector) of a natural gamma-ray flux received by the gamma detector under the condition that the formation and a wellbore are orthogonal is obtained in the effective detection space, and then a corresponding function expression is given by fitting. An integral of a gamma-ray flux received by the detector under the condition of a deviated well is converted into a one-dimensional equivalent integral problem under the condition of a straight well, so as to achieve the fast forward of natural gamma-ray logging of the formation under the conditions of highly-deviated and horizontal wells. This simplified fast forward algorithm can replace a gamma forward method of spherical spatial-division integrals in parallel sedimentary formations, reduce a space-time complexity of algorithms, and improve a calculation efficiency.

Abstract: Prophylaxis and treatment of patients susceptible to infection by coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is achieved using compositions including one or more inhibitors including sulfated glycans and/or highly negative charged compounds. The inhibitors bind to wild-type and variant spike glycoproteins (S-proteins or SGPs) of SARS-CoV-2, inhibiting fusion, entry, and infection of a host cell. The inhibitors can include pentosan polysulfate (PPS), mucopolysaccharide polysulfate (MPS), sulfated lactobionic acid, sulodexide, a defibrotide, 4-t-butylcalix[X] arene-p-sulfonic acid, or combinations thereof. The presence of additional sulfo groups in PPS and MPS contribute to the improved inhibitory activity of compositions with those sulfated glycans against COVID-19 compared with compositions containing heparin alone.

Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via competitive binding to SARS-CoV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-CoV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 ?M, and low cytotoxicity, making it promising for clinical use. While established SARS-CoV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

Abstract: The invention encompasses methods and test strips for detecting the presence of cerebrospinal fluid (CSF) in a biological sample comprising removing sialo-transferrin and selectively detecting or measuring asialo-transferrin in the biological sample.

Abstract: Provided are a conjugate including a core and sialic acids or derivatives thereof bound to the surface of the core, and use thereof. The conjugate provided in the present invention binds with hemagglutinin on the surface of influenza virus to inhibit the course of infection of influenza virus, thereby preventing or treating infection of influenza virus and also preventing or treating infection of influenza virus resistant to antiviral agents. Accordingly, the conjugate may be widely used in the development of prophylactic or therapeutic agents for influenza virus infection.

Abstract: A therapeutic composition includes a polysaccharide, isolated from a member of the genus Cucurbita, e.g., pumpkin, having a backbone including alternating ?-L-rhamnosyl (?-L-Rhap) and ?-D-galactopyranosyluronic acid (?-D-GapA) residues, and a side chain attached to the backbone including ?-D-galactan (?-D-Galp), ?-L-arabinofuranosyl (?-L-Araf), or combinations thereof, and a pharmaceutically acceptable excipient. A ?-D-Galp side chain is attached to the backbone at the C-4 carbon of at least one ?-L-Rhap of the backbone. At least one ?-L-Araf is attached to the ?-D-Galp side chain. The ?-L-Araf is attached to the ?-D-Galp side chain via the C-3 carbon of the ?-D-Galp. The polysaccharide is effective for treating a galectin-3 dependent disorder by binding to the carbohydrate recognition domain of galectin-3, resulting in inhibition of galectin-3 activity.

Abstract: The invention encompasses methods and test strips for detecting the presence of cerebrospinal fluid (CSF) in a biological sample comprising removing sialo-transferrin and selectively detecting or measuring asialo-transferrin in the biological sample.

Abstract: Provided are a conjugate including a core and sialic acids or derivatives thereof bound to the surface of the core, and use thereof. The conjugate provided in the present invention binds with hemagglutinin on the surface of influenza virus to inhibit the course of infection of influenza virus, thereby preventing or treating infection of influenza virus and also preventing or treating infection of influenza virus resistant to antiviral agents. Accordingly, the conjugate may be widely used in the development of prophylactic or therapeutic agents for influenza virus infection.